Messmer K
Institut für Chirurgische Forschung, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Germany.
Infusionsther Transfusionsmed. 1996 Jun;23(3):143-6. doi: 10.1159/000223284.
A Roundtable of Experts in Surgery Blood Management was held 7 to 9 April 1995, in Vienna, where all the available published and unpublished epoetin alfa clinical data was thoroughly discussed and where the following CONSENSUS STATEMENT was developed to give the clinician some practical guidelines for the administration of epoetin alfa in elective surgery patients.
For elective surgery patients it is important to facilitate, via blood conservation methods, the elimination or reduction of exposure to allogeneic blood transfusion and its associated risks. Adjunctive use of epoetin alpha therapy in specific patients is one method to accomplish this goal. Patients with small body size, predicted low blood volume (< or = 51), and/or a hematocrit too low to be enrolled in or to complete their prescribed ABD (autologous blood donation) program especially benefit from epoetin alfa therapy. Generally, epoetin alfa therapy is well tolerated, with an acceptable risk-to-benefit ratio.
1995年4月7日至9日在维也纳举行了外科手术血液管理专家圆桌会议,会上对所有已发表和未发表的促红细胞生成素α临床数据进行了深入讨论,并制定了以下共识声明,为临床医生在择期手术患者中使用促红细胞生成素α提供一些实用指南。
对于择期手术患者,通过血液保护方法促进消除或减少异体输血暴露及其相关风险非常重要。在特定患者中辅助使用促红细胞生成素α疗法是实现这一目标的一种方法。体型小、预计血容量低(≤51)和/或血细胞比容过低而无法参加或完成其规定的自体献血计划的患者尤其受益于促红细胞生成素α疗法。一般来说,促红细胞生成素α疗法耐受性良好,风险效益比可接受。